Tolvaptan-related toxicoderma Alba Rivas Oural; Jose Joaquín Bande Fernández; Luis Fernando Morán Fernández; Sheila Requena López; Blanca Vivanco Allende; Elena Astudillo Cortés;

Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease Borja Quiroga; Patricia Muñoz Ramos; Vicente Álvarez Chiva;

Experience with PCSK9 inhibitors from a Nephrology unit Verónica Escudero Quesada; Jonay Pantoja Pérez; Cristina Castro Alonso; July Vanessa Osma Capera; Alejandro Valero Antón; Asunción Sancho Calabuig;